Medicine
Apidra SoloStar 100 IU/mL injection
Apidra SoloStar 100 IU/mL injection is a prescription medicine containing Insulin glulisine for subcutaneous use, marketed by Sanofi-Aventis, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
conditions are summarized in the following table: Not in-use (unopened)…
Key facts
- Active ingredient (INN)
- Insulin glulisine
- Brand
- Apidra SoloStar
- Strength
- 100 IU/mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 syringe, 5 syringes
- Marketing authorisation holder
- Sanofi-Aventis
- Manufacturer
- Sanofi-Aventis
- Origin register
- US FDA, United States
- Storage
- conditions are summarized in the following table: Not in-use (unopened) Refrigerated (36°F-46°F [2°C-8°C]). Protect from light Not in-use (unopened) Room Temperature (up to 77°F [25°C]) In-use (opened) 10 mL multiple-dose vial Until expiration date 28 days 28 days The in-use time for multiple-dose vial is either 28 days at room temperature up to 77°F (25°C) or 48 hours in insulin pump up…
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A10AB06 Insulin glulisine
- HS code (indicative)
- 3004.31Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 24 February 2009
- Identifiers
- RxCUI 485210, 803194, 847259 +1DailyMed set ID e7af6a7a-8046-4fb4-9979-4ec4230b23aaNDC 0088-2502Application BLA021629
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 syringe, plastic in 1 carton / 3 mL in 1 syringe, plastic | 0088-2502-01 | sanofi-aventis | 24 February 2009 |
| 5 syringe, plastic in 1 carton / 3 mL in 1 syringe, plastic | 0088-2502-05 | sanofi-aventis | 24 February 2009 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Insulin glulisine 100 IU/mL injection.
Clinical summary
Insulin glulisine is an insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. It is available as injection for subcutaneous and intravenous use. MedsAcross supplies Insulin glulisine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Insulin glulisineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Apidra prescribing information (sanofi-aventis) · U.S. National Library of Medicine, DailyMed
- Apidra: European public assessment report (EPAR) · European Medicines Agency
Need Apidra SoloStar 100 IU/mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.